Jeffrey Leiden - Vertex Pharmaceuticals Insider

VRTX -- USA Stock  

USD 180.08  0.44  0.24%

  Chairman
Dr. Jeffrey M. Leiden, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Vertex Pharmaceuticals Incorporated. Dr. Leiden is our Chairman, Chief Executive Officer and President. He has held the positions of Chief Executive Officer and President since February 2012 after joining us as CEO Designee in December 2011. He was a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences VC firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden is a senior advisor to Clarus Ventures. Dr. Leiden serves as a director of Quest Diagnostics Inc., a medical diagnostics company, and Massachusetts Mutual Life Insurance Company, a mutual insurance company. Dr. Leiden was a director and the nonexecutive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012
Age: 61  Chairman Since 2012  Ph.D    
617-341-6100  http://www.vrtx.com
Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.

Jeffrey Leiden Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.49 % which means that it generated profit of $8.49 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 10.67 % meaning that it created $10.67 on every $100 dollars invested by stockholders.
The company currently holds 592.73 M in liabilities with Debt to Equity (D/E) ratio of 21.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals Incorporated has Current Ratio of 3.6 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 10 records

CHAIRMAN Since

Weidong YinSinovac Biotech Ltd
2003
Clay SiegallSeattle Genetics
2004
Jon SaxeSciClone Pharmaceuticals
2009
Yasheng YangOrigin Agritech Limited
2010
Satish ReddyDr Reddys Laboratories Limited
2014
Michael McCallisterZoetis
2015
Roy VagelosRegeneron Pharmaceuticals
1995
Gengchen HanOrigin Agritech Limited
2016
G PrasadDr Reddys Laboratories Limited
2014
Josef RickenbachPAREXEL International Corporati
2012

Entity Summary

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2300 people.Vertex Pharmaceuticals Incorporated (VRTX) is traded on NASDAQ in USA. It is located in 50 Northern Avenue and employs 2,300 people.

Vertex Pharmaceuticals Leadership Team

Paul Silva, Senior Vice President Corporate Controller
William Young, Independent Director
David Altshuler, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
David Greenway, Director
Bruce Sachs, Co-Lead Independent Director
Margaret McGlynn, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Sangeeta Bhatia, Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Cryptocurrency Center

Also Currentnly Active

Purchased a lot of shares of
2 days ago
Traded for 156.0
Purchased a lot of shares of
2 days ago
Traded for 156.0
Purchased over 300 shares of
2 days ago
Traded for 9.81
Also please take a look at World Market Map. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Search macroaxis.com